Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, China.
J Coll Physicians Surg Pak. 2021 Feb;31(2):206-209. doi: 10.29271/jcpsp.2021.02.206.
Ubenimex is widely used as an immunomodulator in the treatment of leukemia and non-small cell lung cancer to improve the anti-tumor treatment effect. However, there has not been any multicenter randomised controlled trials to study its impact on the prognosis of cancer patients. The authors aimed to conduct a meta-analysis to initially study these issues. Pubmed, Cochrane Library and EMbase were searched. Randomised controlled trials of the effects of ubenimex on the survival rate of malignant tumor patients were included in the meta-analysis. Survival rate ratio (OR) and 95% confidence interval (95% CI) between two groups were used to evaluate the efficacy of ubenimex. Fixed effects models were used for meta-analysis. A total of 1,372 cases (684 in the ubenimex group and 688 in the control group) of five studies were included. Between the ubenimex group and the control group, the 1-year OR was 1.40 (95% CI = 1.06 to 1.85), the 2-year OR was 1.43 (95% CI = 1.08 to 1.89) and the 3-year OR was 1.39 (95% CI = 1.07 to 1.81). Standardised treatments combined with ubenimex may improve the survival rate of patients with malignant tumors. Key Words: Malignant tumors, Ubenimex, Randomised controlled trials, Meta-analysis.
乌苯美司广泛用于治疗白血病和非小细胞肺癌的免疫调节剂，以提高抗肿瘤治疗效果。然而，目前还没有多中心随机对照试验来研究它对癌症患者预后的影响。作者旨在进行一项荟萃分析来初步研究这些问题。检索了 Pubmed、Cochrane Library 和 EMbase。纳入了乌苯美司对恶性肿瘤患者生存率影响的随机对照试验进行荟萃分析。使用两组间生存率比值（OR）和 95%置信区间（95%CI）来评估乌苯美司的疗效。采用固定效应模型进行荟萃分析。共纳入 5 项研究的 1372 例病例（乌苯美司组 684 例，对照组 688 例）。乌苯美司组与对照组相比，1 年 OR 为 1.40（95%CI=1.06 至 1.85），2 年 OR 为 1.43（95%CI=1.08 至 1.89），3 年 OR 为 1.39（95%CI=1.07 至 1.81）。标准化治疗联合乌苯美司可能提高恶性肿瘤患者的生存率。关键词：恶性肿瘤；乌苯美司；随机对照试验；荟萃分析。
